Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 4/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17363527 | 0.93 | UMPS (0.57) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL17369135 | 0.93 | UMPS (0.57) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL16871794 | 0.92 | UMPS (0.48) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL16871797 | 0.85 | UMPS (0.57) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL16871796 | 0.85 | UMPS (0.57) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL19689081 | 0.85 | P2RY2 (0.46) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL16871772 | 0.82 | P2RY6 (0.50) | UMPSP2RY2P2RY6P2RY14DNPH1 | |
| SCHEMBL17363837 | 0.81 | UMPS (0.44) | UMPSP2RY2P2RY6P2RY14DNPH1 | |
| SCHEMBL16871835 | 0.80 | UMPS (0.48) | UMPSP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL17369139 | 0.78 | UMPS (0.54) | UMPSP2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | UMPS 548/4885P2RY2 2497/4885P2RY4 894/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | UMPS 559/4885P2RY2 2562/4885P2RY4 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.